Atossa Therapeutics (GB:0HJ7)

Atossa Therapeutics (0HJ7) Income Statement


Atossa Therapeutics Income Statement

Last quarter (Q1 2023), Atossa Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q1, Atossa Therapeutics's net income was $7.92M. See Atossa Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
--$ 0.00$ 0.00$ 0.00$ 0.00
Cost of Revenue
Gross Profit
Operating Expense
$ -442.00K$ 27.69M$ 20.52M$ 14.61M$ 17.27M$ 11.43M
Operating Income
$ -15.85M$ -27.69M$ -20.52M$ -14.61M$ -17.27M$ -11.43M
Net Non Operating Interest Income Expense
$ 1.73M$ 877.00K-$ -938.79K$ 0.00-
Other Income Expense
$ 374.00K$ 146.00K$ -85.00K$ -3.22M$ 25.65K$ 29.30K
Pretax Income
$ -28.45M$ -26.96M$ -20.61M$ -17.83M$ -17.24M$ -11.40M
Tax Provision
$ -27.00K$ -27.00K$ 0.00$ 0.00$ 0.00$ 0.00
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -14.26M$ -26.96M$ -20.61M$ -22.33M$ -17.24M$ -22.88M
Basic EPS
Diluted EPS
Basic Average Shares
Diluted Average Shares
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ -442.00K$ 27.69M$ 20.52M$ 14.61M$ 17.27M$ 11.43M
Net Income From Continuing And Discontinued Operation
$ -28.45M$ -26.96M$ -20.61M$ -17.83M$ -17.24M$ -11.40M
Normalized Income
$ -14.68M-$ -20.61M$ -14.56M$ -17.24M$ -11.40M
Interest Expense
$ -30.30M$ -27.84M$ -20.52M$ -14.61M$ -17.27M$ -11.43M
$ -30.29M$ -27.83M$ -20.50M$ -14.56M$ -17.21M$ -11.39M
Currency in USD

Atossa Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis